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ARTICLE
A virus-encoded type I interferon decoy receptor
enables evasion of host immunity through
cell-surface binding
Bruno Hernáez1, Juan Manuel Alonso-Lobo1, Imma Montanuy1, Cornelius Fischer2,3, Sascha Sauer2,3, Luis Sigal4,
Noemí Sevilla5 & Antonio Alcamí1
Soluble cytokine decoy receptors are potent immune modulatory reagents with therapeutic
applications. Some virus-encoded secreted cytokine receptors interact with glycosami-
noglycans expressed at the cell surface, but the biological signiﬁcance of this activity in vivo is
poorly understood. Here, we show the type I interferon binding protein (IFNα/βBP) encoded
by vaccinia and ectromelia viruses requires of this cell binding activity to confer full virulence
to these viruses and to retain immunomodulatory activity. Expression of a variant form of the
IFNα/βBP that inhibits IFN activity, but does not interact with cell surface glycosaminogly-
cans, results in highly attenuated viruses with a virulence similar to that of the IFNα/βBP
deletion mutant viruses. Transcriptomics analysis and infection of IFN receptor-deﬁcient mice
conﬁrmed that the control of IFN activity is the main function of the IFNα/βBP in vivo. We
propose that retention of secreted cytokine receptors at the cell surface may largely enhance
their immunomodulatory activity.
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The control of primary virus infections in vertebrates oftenrelies on an efﬁcient type I interferon (IFN-I) response.IFN-I is a family of proinﬂammatory cytokines that
are early induced during infection and mainly secreted from
infected cells after recognition of viral products by pattern
recognition receptors (PRRs). Among their pleiotropic effects,
IFN-I (α and β) transmits its signals in healthy cells surrounding
the site of infection through the type I IFN receptor (IFNAR) and
the Jak/Stat signalling pathway to further initiate the transcription
of several interferon stimulated genes (ISGs) that collaborate at
diverse levels to establish an antiviral state and limit viral repli-
cation and spreading1–4.
To overcome the IFN host response, most viruses have
developed diverse strategies aiming to (i) minimise IFN induc-
tion, (ii) block IFN signalling and/or (iii) neutralise the antiviral
activity of some ISGs5–7. Orthopoxviruses (OPVs) provide good
examples of IFN evasion. While IFNs are required for protection
against OPV infections8–10, most members exhibit multiple, and
often redundant, mechanisms to diminish the antiviral action of
IFN (reviewed elsewhere11–14). Among these strategies, the
secretion of soluble proteins that bind IFN-I with high afﬁnities
and prevent its interaction with IFNAR provides an efﬁcient and
straightforward way to counteract this response15–17. Interest-
ingly, although these viral IFN-I binding proteins (IFNα/βBPs),
that serve as decoy receptors, do not share sequence similarity
with the cellular IFNAR, they are highly conserved among
prominent members of this virus genus, such as Variola virus
(VARV), the aetiologic agent of smallpox and one of the most
aggressive pathogens faced by humankind, monkeypox virus
(MPXV) which also results pathogenic for humans, some
strains of Vaccinia virus (VACV), the smallpox vaccine, Ectro-
melia virus (ECTV), the causing agent of mousepox, or cowpox
virus (CPXV)15–18.
The well-characterised secreted IFNα/βBP from VACV, named
B18, lacks a transmembrane domain but is found at the cell
surface. This protein was identiﬁed as the soluble early antigen
from VACV, a protein detected in supernatants and the surface of
infected cells19. The IFNα/βBP binds to the surface of uninfected
cells in the surrounding tissue, thus preventing the IFN-mediated
induction of an antiviral state before cells become infected17,20.
This ability was conﬁrmed for the VARV and MPXV B18
orthologues16. Using a site-directed mutagenesis approach with
VACV B18 and its VARV and MPXV orthologues, we demon-
strated that binding to the cell surface is mediated by glycosa-
minoglycans (GAGs) and occurs through conserved clusters of
basic residues located at the amino terminus of these proteins21.
The interaction of these IFNα/βBPs with GAGs at the cell surface
does not interfere with their ability to bind IFN-I, since mutant
proteins that failed to attach to the cell surface retained the ability
to bind and block IFN-I with high afﬁnity21. In the case of ECTV,
a basic cluster at the amino terminus of its IFNα/βBP is also
present and, although binding to GAGs has not yet been
addressed, this IFNα/βBP has been recently detected on the cell
surface in the spleen and liver of infected mice21,22.
Poxvirus IFNα/βBPs are considered essential for virus viru-
lence, and its key contribution to poxvirus pathogenesis was
demonstrated in two different mouse models by using viruses
lacking IFNα/βBP expression. Deletion of the B18R gene from
VACV caused a 100-fold attenuation in intranasally infected
Balb/c mice15. Moreover, a stronger attenuation (>107-fold) was
obtained for ECTV, since inactivation of the IFNα/βBP gene
resulted in an avirulent variant. Importantly, in contrast to the
full lethality of the wild type (WT) ECTV, all the animals survived
after footpad inoculation with the IFNα/βBP deletion mutant23.
However, the biological relevance of the cell surface binding
properties of the poxvirus IFNα/βBP has never been determined
in the infected animal host.
ECTV, as occurred with VARV and humans, has a narrow
host-range and infection of mice represents a model of
coevolution of a virus with its natural host, and it is considered of
special interest to study viral immune evasion mechanisms24,25.
ECTV inoculation of susceptible mouse strains, such as Balb/c,
results in systemic lethal mousepox, which shares with human
smallpox multiple properties: signs of disease, high mortality rates
and the ability of VACV to protect from infection25–29. These
common features support the value of mousepox as a model for
human smallpox.
ECTV usually enters its host through abrasions in the skin and
after initial replication it migrates to the draining lymph node.
Via efferent lymphatic vessels and blood, the virus reaches major
target organs (spleen and liver) where it massively replicates. If
the animal survives, a second hematogenous spread from these
sites to the skin produces rash and pocks characteristic of poxviral
diseases, such as smallpox and monkeypox.
In the present study we have addressed the aforementioned
question regarding the speciﬁc contribution of the cell surface
binding ability of the IFNα/βBP to poxvirus pathogenesis. Using
both VACV and mousepox infection models, we demonstrate
in vivo that the interaction with GAGs is essential for the
IFNα/βBPs to effectively block the IFN-I antiviral effects during
poxvirus infections.
Results
Cell surface binding of the ECTV IFNα/βBP. We have
demonstrated that B18, the IFNα/βBP from VACV, binds GAGs
at cell surface, and that three basic regions (A, B and C) in the N-
terminus of this viral protein are required for cell interaction, but
not for binding and blocking IFN-I (Fig. 1a and ref. 21). Based on
previous data and the conservation of basic motifs at the amino
terminal region of the ECTV IFNα/βBP21,22, we hypothesised
that E194, the B18 orthologue from ECTV Naval strain (named
E166 in the Moscow strain), behaves like B18. To test this, we
expressed C-terminal V5-6xHis tagged versions of E194 and
E194GAGmut in a baculovirus system. E194GAGmut aims to mimic
the previously generated B18GAGmut, originally named IM15
(Fig. 1a and ref. 21), so that seven basic residues (R or K) from
region A, which is located at the Ig1 domain of E194, were
replaced by alanine (A) (Fig. 1a).
After protein puriﬁcation, we incubated equal amounts of E194
and E194GAGmut with Chinese hamster ovary K1 (CHO-K1) and
HeLa cells, and binding was determined by immunoﬂuorescence
and ﬂow cytometry using anti-V5 antibodies. As negative control
we used an unrelated ECTV protein, a V5-6xHis tagged version
of the poxvirus encoded semaphorin (SEMA). Examination after
incubation with E194 revealed a membrane pattern in both cell
lines, which was not observed with E194GAGmut or SEMA
(Fig. 1b). Flow cytometry analysis in CHO-K1 cells showed a
similar histogram for E194 and B18, conﬁrming that the changes
introduced in E194 to create E194GAGmut completely abolished
its ability to bind to the cell surface (Fig. 1c). We conclude that
E194 attaches to the cell surface, that region A is involved in GAG
binding and that GAGs presumably mediate such interaction.
We next evaluated whether these changes affected the E194
capacity to bind IFN-I and block its antiviral effects. We ﬁrst
determined by surface plasmon resonance (SPR) in a BIAcore
biosensor the kinetic binding parameters of E194 to mouse IFN-α
and compared it to those of E194GAGmut. In both cases, the
recombinant WT protein and its mutant version, the calculated
KD was in the nanomolar range indicating a high afﬁnity for IFN-
I. These results are consistent with those previously determined
for the interaction of VACV B18 and its B18GAGmut derivate with
human IFN-I15,21 (Fig. 2b). Additionally, we determined that
E194 efﬁciently binds human IFNα and β but with reduced
afﬁnity in the case of mouse IFNβ (Supplementary Figure 1), as
described for B1815 and coincident with previous data using
supernatants from ECTV infected cells18.
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We then tested the ability of E194 to block the IFN-induced
antiviral cell response. As expected, IFN treatment protected cells
from vesicular stomatitis virus (VSV) infection (Fig. 2b, left panel).
In contrast, preincubation of IFN with increasing amounts of
E194, similar to B18, diminished the protective effect of IFN and
cells died after VSV challenge in a dose-dependent manner
(Fig. 2b, left panel). This capacity was not affected by the
introduced changes abolishing its cell surface binding ability, since
E194GAGmut also blocked the IFN-mediated cell protection
(Fig. 2b, left panel). On the other hand, using a modiﬁed version
of this assay, in which cells were ﬁrst incubated with recombinant
viral proteins and extensively washed prior the IFN addition, we
found that E194GAGmut was no longer able to counteract the IFN
protective effect against VSV infection (Fig. 2b, right panel). WT
B18 and E194 proteins were retained at the cell surface, whereas
the E194GAGmut protein was removed after extensive washing of
the monolayer and no longer inhibited the IFN effects. In
summary, we conclude that the GAG-binding properties described
for the VACV IFNα/βBP21 are extended to the ECTV IFNα/βBP.
Viruses expressing an IFNα/βBP unable to interact with GAGs.
IFNα/βBP has been already shown to be relevant for VACV
and ECTV virulence in mouse models of infection15,23. Aiming
to discriminate the speciﬁc relevance of the interaction of
the IFNα/βBP with GAGs at cell surface during poxvirus infec-
tions we generated mutant VACV and ECTV expressing the
GAG-binding deﬁcient versions of the IFNα/βBP. The VACV
IFNα/βBP deletion mutant (VACVΔB18), referred here as
VACVΔIFNα/βBP, was previously described15 and we con-
structed a new ECTV IFNα/βBP (E194) deletion mutant in the
Naval strain, referred to here as ECTVΔIFNα/βBP, since previous
work has been done with ECTV Moscow strain23. We introduced
in the IFNα/βBP gene locus of the deletion mutant viruses the
corresponding sequences encoding variant IFNα/βBPs lacking the
ability to bind to the cell surface, generating the recombinant
viruses VACVIFNα/βBPGAGmut and ECTV IFNα/βBPGAGmut
(Supplementary Figure 2). The genome sequence of the recom-
binant viruses constructed was fully sequenced to conﬁrm the
correct deletion or insertion of genes and the absence of addi-
tional mutations.
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Fig. 1 Cell surface interaction of the IFNα/βBP from ECTV. a Partial amino acid sequence of the IFNα/βBP from VACV (B18) and ECTV (E194). Shaded
boxes indicate the putative GAG binding regions A, B and C identiﬁed in the amino terminal sequence of the proteins. Amino acid substitutions of basic
residues performed to generate their corresponding mutant proteins B18GAGmut and E194GAGmut are underlined. b The indicated cells were incubated at
4 °C for 30min with V5-tagged recombinant proteins E194 and E194GAGmut, and then extensively washed. Proteins were detected by immunoﬂuorescence
with an anti-V5 monoclonal antibody and cell nuclei were stained with DAPI. The unrelated viral protein SEMA was used as negative control. c CHOK1 cells
were incubated with recombinant tagged proteins on ice and extensively washed, and the binding to cell surface was assessed by ﬂow cytometry using an
anti-V5 antibody. VACV B18 protein was incorporated as positive control. Shaded histograms correspond to the indicated protein while non-shaded
correspond to untreated cells. In every case, experiments were performed in triplicate and a representative histogram is shown
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To assess whether VACV and ECTV replication in cell culture
was affected by the genomic changes, BSC-1 cells were infected
with the recombinant viruses at low m.o.i. (0.01 pfu/cell), and
virus yields determined by plaque assay at diverse times
postinfection. No signiﬁcant differences were found in the
replication of the mutant viruses when compared to WT viruses
(Fig. 3a, left panels). Similar results were obtained after infection
of cells at high m.o.i. (5 pfu/cell), since no differences were found
in the production of cell-associated virus and extracellular virus at
24 hpi (Fig. 3a, right panels). These results showed that
expression of the variant form of IFNα/βBP does not affect virus
replication in cell culture.
We analysed the supernatants from cells infected with these
mutant viruses to test their capacity to block the IFN-induced
protective effects against VSV (Fig. 3b). As expected, preincubation
of IFN-I with supernatants from cells infected with VACVΔIFNα/
βBP and ECTVΔIFNα/βBP did not prevent the IFN-mediated
protection. On the contrary, supernatants from infections with
viruses expressing the IFNα/βBPGAGmut, VACVIFNα/βBPGAGmut
and ECTVIFNα/βBPGAGmut, acted like those from their corre-
sponding WT viruses and were able to prevent the protective action
of IFN-I against VSV (Fig. 3b, left panels). However, in the washing
assay we found that supernatants from cells infected with
VACVIFNα/βBPGAGmut and ECTVIFNα/βBPGAGmut were unable
to block the protective effect of IFN-I against VSV, while those from
WT viruses still retained the IFN-blocking capacity (Fig. 3b, right
panels). Together these results indicated that (i) all viruses replicate
similarly in cell culture, (ii) the WT and variant forms of the
IFNα/βBPs are not required for infection in cell culture, and (iii)
the IFNα/βBPGAGmut versions are correctly synthesised by the
engineered viruses during infection.
IFNα/βBP binding to cell surface contributes to virulence. To
evaluate the contribution of the interaction of the IFNα/βBPs
with cell surface GAGs to poxvirus virulence we used two models
of infection. In the case of VACV, we used the intranasal (i.n.)
infection model, where mice were infected with 105 pfu of the
WT and mutant viruses (Fig. 4). Coincident with previous
results15, all animals infected with WT VACV succumbed to
infection, whereas infection with VACVΔIFNα/βBP did not cause
any mortality and mice showed no weight loss and limited signs
of illness (Fig. 4a). Interestingly, although animals inoculated with
VACVIFNα/βBPGAGmut showed clear signs of infection and
weight loss, only one of these animals died (Fig. 4a) indicating an
attenuated phenotype of VACVIFNα/βBPGAGmut similar to that
observed with the IFNα/βBP deletion mutant.
In the case of ECTV, we used the classical mousepox model
of subcutaneous (s.c.) inoculation in the footpad, with viral
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Fig. 2 IFN-I binding properties of the variant E194 protein unable to interact with GAGs. a SPR sensorgrams and ﬁtting obtained for the determination of the
kinetic constants of the interaction of E194 and E194GAGmut recombinant proteins with mouse IFNαA. E194 or E194GAGmut were immobilised in a SPR
Biacore SA sensor chip and binding and dissociation of several concentrations of mouse IFNαA at 30 μl/min were recorded and adjusted to a 1:1 Langmuir
ﬁtting (solid lines). The nanomolar concentration corresponding to each sensorgram is indicated. Kinetic parameters and calculated afﬁnity constants of
E194 and E194GAGmut are shown in the inset and compared to those previously described for the interaction of human IFNα-2b with VACV B18 and
B18GAGmut (originally named IM15). b To determine the IFN-I blocking activities, in the preincubation assay (left), increasing amounts of recombinant
proteins were incubated with 50 U of mouse IFNαA and the mixture added to L929 cells. After 16 h incubation, cells were infected with VSV and cell
viability measured at 72 hpi. In the washing assay (right), cells were incubated with recombinant proteins, extensively washed, and then incubated with 50
U of mouse IFNαA as described for the previous assay. In both assays, untreated (IFN -) or IFN-I treated (IFN+ ) cells, and also the addition of B18
recombinant protein were incorporated as controls. Data are means showing standard deviations of two independent experiments performed in triplicate
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doses ranging from 10 to 106 pfu. The inoculation of 10 pfu of
WT ECTV resulted in 100% lethality by 10 dpi, whereas all the
animals infected with ECTVΔIFNα/βBP survived the infection
even with 106 pfu (Fig. 4b). As observed with VACV,
ECTVIFNα/βBPGAGmut was highly attenuated, even at the
highest dose of 106 pfu where only one animal died (Fig. 4b).
These results showed that both IFNα/βBPGAGmut-expressing
mutant VACV and ECTV were highly attenuated to levels
similar to those found with the corresponding IFNα/βBP
deletion mutants.
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NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07772-z ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5440 | https://doi.org/10.1038/s41467-018-07772-z | www.nature.com/naturecommunications 5
In the case of ECTV infections, an important difference
regarding illness severity was observed when comparing the two
modiﬁed viruses. Mice infected with the highest dose of
ECTVΔIFNα/βBP did not exhibit weight loss below 95% of the
original values or other signs of illness characteristics of
mousepox, with the exception of a strong footpad swelling not
observed in the WT virus infection. Interestingly, this increase in
footpad swelling appeared along with a pronounced weight loss
and severe signs of illness in mice infected with ECTVIFNα/
βBPGAGmut (Fig. 4b, c). The magnitude of the disease produced
by this mutant virus was dependent on the dose inoculated. While
infection with low viral doses (10 or 102 pfu) did not result in
weight loss or signiﬁcant signs of illness, mice infected with doses
higher than 104 pfu exhibited weight loss from 4–5 dpi to later
drop to nearly 80% of their initial value, and illness scores peaked
at 10–14 dpi at around 2.5 (scale: 0 for healthy animals and 4 for
severely sick animals). Despite this severity of infection, all the
ECTVIFNα/βBPGAGmut infected mice started to recover from
disease and increased bodyweight from 16 dpi (Fig. 4 and
Supplementary Figure 3).
Collectively, these results evidenced that the ability of the
IFNα/βBP to interact with the cell surface strongly contributes to
poxvirus disease. To discriminate whether this attenuation of
poxviruses expressing the IFNα/βBPGAGmut is due to IFN-I
modulation or to an unknown function associated to the cell
surface attachment of the IFNα/βBP, we evaluated the virulence
of ECTV expressing the IFNα/βBPGAGmut in a host lacking IFN-I
signalling. To this effect, mice deﬁcient in subunit 1 of IFNAR
(IFNAR1) were infected s.c. in the footpad with 102 pfu. We
found that viruses expressing either no IFNα/βBP or IFNα/
βBPGAGmut recovered its virulent phenotype and killed all mice
between 7 and 9 dpi, as observed with WT ECTV (Fig. 5). These
results support the idea that the ECTVIFNα/βBPGAGmut
attenuation in WT susceptible mice is due to a reduced IFN-I
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Fig. 4 The IFNα/βBP cell surface binding activity contributes to poxvirus pathogenesis. Balb/c mice (n= 5) were infected i.n. or s.c. in the footpad with the
indicated VACV (105 pfu) (a) or ECTV (10 pfu of WT and 106 pfu of the IFNα/βBP mutants) (b), respectively. Mice were monitored daily for survival,
bodyweight and signs of illness, and footpad swelling in the case of ECTV. Weight data are expressed as the mean ±SD of the ﬁve animals weights
compared to their original weight at the day of inoculation. Signs of illness, as a score ranging from 1 to 4, and the size of the footpad (mm) where
inoculation was performed are also expressed as the mean of the ﬁve animals. Statistical analyses performed were multiple t-tests with FDR Q= 1% and
days at which signiﬁcant differences (p < 0.05) were found between IFNα/βBPGAGmut and WT or ΔIFNα/βBP infections are indicated with solid or dotted
lines, respectively. One representative experiment of two is shown
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blocking ability when the IFNα/βBP is unable to attach to the cell
surface.
IFNα/βBP cell surface attachment affects virus dissemination.
ECTV footpad inoculation mimics natural infections and is an
excellent model to examine whether the IFNα/βBP interaction with
the cell surface is required for in vivo virus spread within the
infected animal. Following footpad inoculation of ECTV in sus-
ceptible mice, the virus replicates at the site of infection before
reaching the popliteal lymph node. From this point, the virus
disseminates via the efferent lymphatics and bloodstream to invade
the spleen and liver, where massive replication occurs30–32. We
infected Balb/c mice in the footpad with 103 pfu of ECTV, ECT-
VΔIFNα/βBP or ECTVIFNα/βBPGAGmut, and virus yields from
footpad, spleen and liver were titrated at 5 and 7 dpi. Coincident
with previous data23, no differences among the three viruses were
observed at both times postinfection in footpads, indicating that the
IFNα/βBP function is not required for the initial virus replication
(Fig. 6, left panels). However, important differences were found in
major target organs. In the absence of the IFNα/βBP, viral titres at 5
dpi were 4 and 3 log lower in spleen and liver, respectively, com-
pared to WT virus infection and titres in both organs were under
the detection limit of the assay at 7 dpi (Fig. 6, central and right
panels). In the case of ECTVIFNα/βBPGAGmut, we observed a
discrete reduction in viral titres at 5 dpi compared to WT ECTV,
which was much more evident (3 log reduction) in both organs at 7
dpi, suggesting a role for IFN-I in virus clearance in these major
target organs between 5 and 7 dpi (Fig. 6, central and right panels).
The spleen and liver from ECTVΔIFNα/βBP infected mice exhib-
ited a healthy appearance, similar to that observed in mock-infected
mice, and completely different to the reduced size and necrotic
aspect characteristic of WT ECTV infections. However, the spleen
and liver from the ECTV-IFNα/βBPGAGmut-infected animals
showed an unhealthy intermediate appearance between ECT-
VΔIFNα/βBP- and ECTV-infected animals, with limited liver
damage and enlarged spleens (Supplementary Figure 4).
The above data indicated a restriction in virus dissemination
from the initial site of replication to major target organs after
infection with ECTVIFNα/βBPGAGmut. Thus, to ascertain whether
an efﬁcient blocking of IFN-I facilitates poxvirus replication in
these major target organs, we circumvented the natural route
of ECTV infection by intravenous (i.v.) inoculation of mice.
Intravenous inoculation of 5 × 103 pfu of ECTV resulted in the
early appearance of signs of illness (3 dpi) and weight loss, leading
to 100% mortality with a mean time of death of 8 dpi (Fig. 7). As
found in the footpad model of infection, ECTVΔIFNα/βBP was
highly attenuated in the i.v. model and mortality was importantly
diminished (30%) after inoculation with ECTVIFNα/βBPGAGmut,
showing an extended mean time of death of 10 dpi. Again, similar
differences to those described above in terms of disease severity
were appreciated here, since the signs of disease resulted more
evident in the ECTVIFNα/βBPGAGmut -infected than in the
ECTVΔIFNα/βBP-infected animals (Fig. 7). Additionally, after i.v.
inoculation with lower doses (5 x 102 pfu) 37% of the animals
survived to WT infection, whereas no deaths were observed with
both ECTVΔIFNα/βBP and ECTV-IFNα/βBPGAGmut. These data
indicated that an efﬁcient IFN-I blocking mediated by IFNα/βBP
and its cell attachment ability is critical for poxvirus replication in
the major target organs.
Expression of a cell-surface mutant IFNα/βBP increases sys-
temic anti-IFN activity. Binding to GAGs might allow retention
of the poxviral IFNα/βBP to locally increase its IFN blocking
function at sites of virus replication. Thus, abrogation of the cell
surface attachment properties of the IFNα/βBP may result in
increased systemic dispersion of the anti-IFN activity in the
bloodstream during infection. To evaluate this hypothesis we
tested the IFN protection activity in plasma from infected animals
at 5 dpi. The levels of protection against IFN determined in the
case of VACV expressing the IFNα/βBPGAGmut were signiﬁcantly
increased compared to those found in the WT infection (Fig. 8a),
indicating a higher prevalence of the IFNα/βBP in serum after
abrogation of its GAG binding ability. We found more variability
in ECTV-infected animals, although the data again suggested a
higher prevalence in plasma from mice infected with a virus
expressing the mutant version of the IFNα/βBP compared to
infection with a virus expressing the WT protein (Fig. 8b). In this
case, four out of ﬁve ECTVIFNα/βBPGAGmut -infected animals
analysed exhibited higher protection levels against IFN than the
mean value from WT ECTV infections.
Lack of IFNα/βBP cell binding elicits an IFN host response. To
determine whether the lack of cell surface attachment properties
in the IFNα/βBP directly impacts on the IFN-induced host
response, differential expression analyses using RNA-seq were
undertaken on cervical lymph nodes, spleen and lung tissues from
mice mock-infected or intranasally infected with VACV or the
IFNα/βBP mutant viruses. Comparison of host gene transcription
in mock-infected mice with that from mice infected with
VACV, VACVΔIFNα/βBP or VACVIFNα/βBPGAGmut identiﬁed
signiﬁcant differentially expressed genes (SDEGs). Pathway
enrichment analysis performed with those SDEGs retrieved a
number of pathways related to the biological function of the IFN
in those infected animals, including IFN signalling, Role of
pathogen recognition receptors (PRRs) or Activation of IRF by
cytosolic PRRs, among others (Fig. 9a).
Similar z-score values for these pathways were determined for
VACVIFNα/βBPGAGmut and VACVΔIFNα/βBP infections in the
lymph nodes, spleen and lung samples, indicating a clear and
similar activation of these IFN related pathways. On the contrary,
no activation (lymph node and spleen) or lower z-scores (lung)
were determined for the WT infection (Fig. 9b). Importantly,
upstream regulator analysis with splenic samples showed
increased z-scores activation values for relevant transcription
factors of the IFN response (IRF1, IRF3, IRF5, and IRF7), and
also central genes in IFN signalling (IFN-I, IFNAR, and STAT1).
However, the activation values for TRIM24, a negative regulator
of the IFN/STAT pathway, were found diminished after infection
with both IFNα/βBP mutant viruses compared to WT virus
(Fig. 9c). Accordingly, 39.8% of the upregulated SDEGs (177/444)
in VACVIFNα/βBPGAGmut-infected spleens compared with WT
infections were determined as ISGs regulated by IFN-I using
Interferome 2.033. Similar results were found in the other tissues
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analysed, infected lymph nodes and lungs (Supplementary
Table 1). Finally, expression levels of some selected ISGs were
found increased after infection with VACVIFNα/βBPGAGmut and
VACVΔIFNα/βBP, indicating a stronger IFN-induced response
compared to WT VACV infection (Fig. 9d). These results
indicated that the cell attachment properties in the IFNα/βBP are
crucial to efﬁciently prevent the IFN induced host response
during poxvirus infections.
Discussion
The activity of the viral IFNα/βBP represents a potent and crucial
immunomodulatory mechanism to evade the host innate immune
IFN response during infection, and one of the most important
virulence factors described to date for poxvirus infections of mice,
since its absence results in up to 106 fold attenuation15,23.
Moreover, antibodies against this protein block its biological
activity and efﬁciently protect mice from mousepox, conﬁrming
its contribution to virulence22. A similar degree of attenuation of
ECTV has been recently reported after deletion of the gene
encoding a viral homologue of the cellular tumour necrosis factor
receptor, named cytokine response modiﬁer D (CrmD), that
inhibits TNF but also a set of chemokines through a unique
chemokine binding domain, named smallpox virus-encoded
chemokine binding (SECRET) domain34. These reports high-
light the relevance of IFN-I, TNF and chemokines working
together in the protective immune response against poxvirus
infections, similar to the link described for IFN-I and nuclear
factor kappa B pathways35.
The ability of the viral IFNα/βBP to attach to surfaces of non-
infected and infected cells, where additionally exerts its inhibitory
function, has long been known, however the speciﬁc contribution
of this feature of the viral IFNα/βBP to pathogenesis remained
undetermined16,17,20. We have addressed this question using
engineered VACV and ECTV expressing mutant versions of the
IFNα/βBP that no longer interact with the cell surface, and we
demonstrate that this property of the viral IFNα/βBP is essential
to prevent the IFN-I host response in both mouse models of
infection. The attenuation phenotypes obtained for these mutant
viruses were comparable to those of their correspondent IFNα/
βBP deletion mutant viruses, revealing that binding IFN-I with
high afﬁnity is crucial, but not sufﬁcient, to efﬁciently evade the
IFN-I antiviral effects in vivo. This surprising result demonstrates
that the localisation of the viral IFNα/βBP at the cell surface is
required to efﬁciently fulﬁl its biological function in vivo.
As described for other GAG binding proteins, such as growth
factors or chemokines36,37, the binding to the cell surface may
potentially confer diverse advantages to the viral IFNα/βBP
during infection, functioning as a retention and clustering
mechanism to act mainly within infected areas, for protection
against circulating plasma proteases or to allow interactions with
other molecules, in addition to IFN-I. In the case of the viral
IFNα/βBP, our results using IFNAR deﬁcient mice indicate that
the main function of this protein at the cell surface is the
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prevention of IFN-I signalling. In agreement with this, previous
transcriptomics (RNA-seq) studies showed the absence of host
gene expression changes after binding of the viral IFNα/βBP to a
mouse cell line38. Thus, the beneﬁts obtained after attachment to
the cell surface would be restricted to the local enhancement of
the inhibitory function of the viral IFNα/βBP and the abrogation
of its GAG binding properties leads to a protein which is no
longer able to control the IFN-I response during infection. This
decrease in IFN-I inhibitory function in cell culture would explain
that infection of mice with both the deletion mutants and the
IFNα/βBPGAGmut expressing viruses resulted in a dramatic
attenuation phenotype compared to WT virus infections. The
IFN-I activation in mice infected with the IFNα/βBPGAGmut
expressing viruses is expected to enhance T (CD8+, CD4+) and
NK cell responses, as shown in mice infected with an ECTV
IFNα/βBP mutant23. The interaction of the IFNα/βBP with GAGs
may interfere with attachment of chemokines to the cell surface,
as proposed for some viral CKBPs39. Although the IFNα/βBP will
mask a reduced number of GAG-binding sites at the cell surface,
we cannot rule out the possibility that the binding of IFNα/βBP to
GAGs may have some indirect effect on chemokine-mediated
leucocyte migration to sites of infection.
Virus dissemination is signiﬁcantly impaired after infection in
the absence of a fully functional viral IFNα/βBP. Viral loads in
major target organs from animals infected with the IFNα/βBP
deletion mutant virus dropped to undetectable levels between 5 and
7 dpi, suggesting a role for the IFN system in virus clearance that
would support the lack of evident mousepox disease. In the case of
the sole abrogation of the viral IFNα/βBP cell attachment proper-
ties, the viral loads in spleen and liver, although clearly reduced
compared to WT infection, still remained detectable at 7 dpi
indicating a loss of viral IFNα/βBP effectiveness to prevent the IFN
effects. This level of viral replication, coincident with limited liver
damage and enlarged spleens, may account for the signs of illness
observed in mice infected with the IFNα/βBPGAGmut expressing
viruses. In addition to this reduction of virus titres in major target
organs, we detected by RNA-seq the activation of an IFN based
response in spleen, comparable to that elicited by the infection in
the absence of the viral IFNα/βBP, supporting the idea that after
abrogation of its cell attachment properties the IFNα/βBP is not
able to control the IFN host response and the subsequent virus
clearance from major target organs.
Attachment to cell surfaces through GAG interactions is not a
unique feature of the viral IFNα/βBP, and the conclusions from
the present study could be applied to other poxvirus secreted
immunomodulatory proteins that also exhibit this ability39. The
IL-18 binding protein from Molluscum contagiousm virus and
VARV neutralises IL-18 induced-effects, either as soluble or
membrane anchored form, acting as a decoy receptor as shown
for the viral IFNα/βBP40,41. Other examples include E163 from
ECTV and M-T1 from MYXV, chemokine-binding proteins able
to bind simultaneously chemokines and GAGs at the endothe-
lium cell surface42–44, and the poxviral complement inhibitor
from VACV and VARV, exerting its function at the cell surface
after GAG binding45,46. In each case, the phenotype attributed to
the virus deletion mutants in these immunomodulators resulted
attenuated to different degrees, revealing their contribution to
poxvirus pathogenesis47–52, however there is no data concerning
the speciﬁc contribution of their GAG-binding properties. In the
case of VCP, the attachment to cell surface may also occur in a
GAG-independent fashion, through disulphide bond interaction
with the VACV transmembrane protein A5653. A VACV mutant
expressing a variant of VCP lacking cell surface localisation
resulted in an attenuated phenotype similar to that of the VCP
deletion mutant after i.n. inoculation of mice, and produced
intermediate sized lesions between the deletion mutant and the
WT viruses in a intradermal model of infection51. But this study
was not conclusive because the VCP mutagenesis performed
affected not only the binding to the cell surface but also its
dimerisation ability, which is known to potentiate the VCP action
and is mediated by the same amino terminal-free cysteine. In this
case, it seems difﬁcult to discern the speciﬁc contribution of cell
surface attachment to pathogenesis. Instead, the viral IFNα/βBP
has been proved to be a suitable immunomodulatory protein to
test the contribution of its cell attachment properties to poxvirus
virulence.
IFN-I signalling has emerged as an important and central
pathogenic factor in the course of a variety of diseases, especially
a
5×102 pfu 5×103 pfu
Survivors MTD Survivors MTD
ECTV 37% (3/8) 12.4 0% (0/10) 8
ECTVΔIFNα/βBP
ΔIFNα/βBP
100% (6/6) 0 100% (10/10) 0
ECTV-IFNα/βBPGAGmut
IFNα/βBPGAGmut
100% (8/8) 0 70% (7/10) 10.3
Intravenous inoculation
b Mock ECTV
0 2 4 6 8
0
1
2
3
dpi dpi
Si
gn
s 
of
 ill
ne
ss
0 2 4 6 8
0
25
50
75
100
%
 S
ur
viv
al
0 2 4 6 8 10 12 14 16 10 12 14 16 10 12 14 1618
80
90
100
110
dpi
%
 In
itia
l w
e
ig
ht
Fig. 7 Infection by i.v. inoculation of ECTV IFNα/βBP mutants. Balb/c mice were i.v. infected with 5 × 102 or 5 × 103 pfu of the indicated ECTV mutants. a
Survival rates and mean time to death (MTD)±SD from three independent experiments are shown. b A representative experiment of two showing weight
loss, clinical signs and survival from animals infected with 5 × 103 pfu of the ECTV mutants
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07772-z ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5440 | https://doi.org/10.1038/s41467-018-07772-z | www.nature.com/naturecommunications 9
autoimmune and autoinﬂammatory disorders, such as systemic
lupus erythematosus (SLE), type 1 diabetes or Sjogren’s syndrome
among others54,55. The current therapeutic approaches, some of
them already in phase III clinical trials, for the treatment of these
interferonopathies involve the targeting of IFN-I using either
monoclonal antibodies against IFN-α or its receptor IFNAR, and
even the induction of polyclonal anti-IFN-I neutralising antibodies
after administration of inactivated cytokine derivatives or kinoids.
However, in the case of SLE, these therapies based on monoclonal
antibodies failed to completely subvert the IFN-I gene signature,
which is a hallmark in SLE patients56. A possible explanation is that
IFN-β and other IFN-α isoforms still remained active after treat-
ment, and in this sense poxvirus IFNα/βBPs exhibit an additional
advantage over monoclonal antibodies since they bind multiple
forms of IFN-I15,50. In addition, the VACV IFNα/βBP has been
recently shown to alleviate neurotoxicity and histopathological
complications originated by the IFN-I upregulation in an HIV
encephalitis mouse model and the viral soluble decoy receptor has
been proposed as a viable therapeutic alternative to monoclonal
antibodies against IFN-I57,58. We have demonstrated here that an
engineered viral IFNα/βBP, lacking cell attachment properties while
maintaining intact its IFN-I binding ability, is much less efﬁcient
than the unmodiﬁed version to prevent the host IFN-induced
antiviral response during poxvirus infections. However, the GAG
binding mutant may still represent a more potent inhibitor in anti-
IFN therapeutics for these disorders, since it might potentially exert
its inhibitory function at more distant tissues than the unmodiﬁed
viral IFNα/βBP version. Of broader interest, the identiﬁcation of
GAG-binding activities in human secreted cytokine decoy receptors
or the addition of a GAG-binding domain deserves to be investi-
gated in order to address whether the cell-binding activity may
improve the therapeutic value of cytokine decoy receptors.
In summary, we show the critical role that the GAG-binding
activity of a viral secreted IFN-I decoy receptor has on its ability
to control the IFN response in vivo, illustrating the relevance of
the cell surface binding activity. Our ﬁndings raise the possibility
that the GAG-binding properties, either natural or engineered, of
human soluble cytokine receptors may also be relevant to achieve
their full immunomodulatory activity.
Methods
Cells and viruses. BSC-1 (ATCC CCL-26), HeLa (ATCC CCL-2), Vero (ATCC
CCL-81) and mouse L929 cells (ATCC CCL-1) were maintained in 10% foetal
bovine serum (FBS) containing DMEM. CHO-K1 cells were kindly provided by Dr.
Arenzana-Seisdedos (Institute Pasteur, Paris, France) and were grown in 10% FBS
containing DMEM-Ham′s F12 (1:1) medium. Hi5 insect cells were cultured in TC-
100 medium supplemented with 10% FBS The sources of virulent VACV Western
Reserve strain and the corresponding VACV mutant lacking IFNα/βBP expression
(VACVΔIFNα/βBP) were previously described15. The source of ECTV strain Naval
was described59. VACV and ECTV were grown in BSC-1 cells, and viral stocks
were partially puriﬁed by centrifugation through a 36% sucrose cushion and stored
in Tris-HCl pH 9.0 at −80 °C. Viral stocks were titrated twice by plaque assay in
monolayers of BSC-1 cells prior to animal infections. To this effect, serial dilutions
of the virus stock were plated on duplicate BSC-1 cell monolayers in semi-solid
carboxy-methyl cellulose media with 2.5% FCS. Cells were ﬁxed in 10 % for-
maldehyde at 6 dpi and plaques were stained with 0.1% (w/v) crystal violet. VSV
strain Cocal was obtained from Dr. William James (Sir William Dunn School of
Pathology, Oxford University, Oxford, UK). Both VSV growth and titration by
plaque assay were carried out in Vero cells.
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Fig. 8 Detection and biological action of the IFNα/βBP in plasma from infected animals. Dilutions containing 20% of plasma from mice infected with the
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Construction of recombinant poxviruses. Recombinant ECTVs were generated
using ECTV-Naval as parental virus and a transient dominant selection procedure
based on puromycin resistance to avoid the presence of foreign DNA sequences in
the genome of the ﬁnal recombinant ECTV60. Brieﬂy, to generate ECTVΔIFNα/
βBP, BSC-1 cells were infected with ECTV-Naval (0.01 pfu/cell) and at 1 hpi
transfected with pBH13 using Fugene HD (Invitrogen), following the manufacturer
indications. The plasmid pBH13 is based on pMS30 and contains a 927 nt fragment
and a 883 nt fragment corresponding to 5′ and 3′ ﬂanking regions of EVN194 gene
(184,716 to 185,635 bp and 186,557 to 187,449 bp positions in the ECTV Naval
genome)59, together with a downstream cassette including the enhanced green
ﬂuorescence protein (EGFP) marker under the control of an OPV early/late syn-
thetic promoter and the puromycin resistance gene. When cytopathic effect was
complete, cells were harvested and used as inoculum in ﬁve consecutive rounds of
infection in the presence of 10 μg/ml puromycin monitoring EGFP expression.
ECTVΔIFNα/βBP was ﬁnally isolated by three successive plaque puriﬁcation steps
of white plaques in the absence of puromycin.
To generate ECTVIFNα/βBPGAGmut a similar procedure was used, but this time
with pBH17 as the vector and ECTVΔIFNα/βBP as parental virus. The plasmid
pBH17 carries the sequence encoding E194GAGmut, which had been ﬁrst ampliﬁed
by PCR from vector pIM26 (see below) and inserted between the previously
indicated ﬂanking regions in pBH13.
In the case of VACVIFNα/βBPGAGmut, BSC-1 cells were infected with
VACVΔIFNα/βBP15 and transfected with pIM33. The plasmid pIM33 contains the
nucleotide substitutions in B18R generated with the QuickChange II site-directed
mutagenesis kit (Stratagene), using the oligonucleotides 5′-GGTTAAATGGGAA
GCGCTAGAAGCAAATGCAGCGGCACAGGTTTCTAATGCAGCTGTTGCAC
ATGTGATTTATGG -3′ and 5′-CCATAAATCACCATGTGCAACAGCTGCATT
AGAAACCTGTGCCGCTGCATTTGCTTCTAGCGCTTCCCATTTAACC -3′
and the plasmid pAA21 as template15. The recombinant virus was isolated by the
transient dominant selection procedure based on mycophenolic acid resistance
mediated by the E. coli gpt gene as described61. A schematic genomic
representation of the poxviruses used is shown in Supplementary Figure 2.
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sample with the mock-infected samples. b Activation z-scores determined for the Interferon Signalling pathway and corresponding to each VACV infected
sample after comparison to mock infection. c SDEGs were analysed by the IPA upstream regulator function (direct only) and the activation z-score values
for the selected upstream regulators determined for VACV-WT (black bars), VACVΔIFNα/βBP (white bars) and VACVIFNα/βBPGAGmut (grey bars)
infections are shown. d Heatmap showing the expression values (log2FC) of the selected ISGs in the indicated VACV infected tissues
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The genome from the recombinant VACV and ECTV generated was fully
sequenced with the Illumina sequencing technology to conﬁrm the genetic
structure of the viruses and the absence of inadvertent mutations that may have
been introduced during the generation of recombinant viruses.
Virus growth curves. BSC-1 cells were infected for 1 h at 37 °C at high m.o.i. (5
pfu/cell) or low m.o.i. (0.01 pfu/cell) in the one-step or multi-step growth curves,
respectively. Cells were then washed and fresh medium was added. In the one-step
growth curve, at indicated times post-infection, the medium was harvested and
centrifuged at 1800 × g for 5 min to pellet detached cells. These cells were combined
with infected cells that had been scraped from the plate into 0.5 ml of fresh
medium. In the multi-step growth curve, cells and media were together harvested
at indicated times. In all cases, samples were frozen, thawed three times and titrated
on BSC-1 cells in duplicates.
Mice. Balb/c female mice were purchased from Charles River. The IFNAR deﬁcient
mice (ifnar1 −/−) on a C57BL/6 genetic background9 were bred and maintained in
the animal facilities of Instituto Nacional de Investigación y Tecnología Agraria y
Alimentaria (INIA). All mice used in experiments were 5–8 weeks old.
Ethical statement. All animal experiments were performed with special efforts to
minimise animal suffering, in compliance with national and international regula-
tions and were approved by the Ethical Review Board of Consejo Superior de
Investigaciones Cientíﬁcas and Comunidad de Madrid under reference PROEX
025/16.
Infection of mice and tissue processing. The infections of groups of ﬁve animals
per condition were performed with sucrose-puriﬁed virus diluted in PBS con-
taining 0.1% bovine serum albumin. Mice were anaesthetised with isoﬂuorane and
then infected by s.c. inoculation into the footpad in the case of ECTV or i.n.
infected in the case of VACV, with 10 μl of virus inoculum containing the indicated
infectious doses. When indicated, i.v. infection of Balb/c mice with ECTV was
performed by injection of 50 μl of virus inoculum containing 5 × 103 pfu into the
tail vein. Mice were housed in ventilated racks under biological safety level 3
containment facilities and monitored daily for survival, weight and signs of disease.
For determination of virus titres in organs, infected mice were euthanized at 5
and 7 dpi by CO2 asphyxiation, and a sample of the indicated organs from each
animal were aseptically removed. Samples were weighed, homogenised in 1 ml PBS,
and freeze/thawed 3 times. Then, the amount of infectious virus was determined by
plaque assay as described above. For determination of anti-type I IFN activity in
infected mice, plasma was prepared from nearly 1 ml of blood at 5 dpi by
centrifugation at 14,000 × g for 10 min at 4 °C.
Expression and puriﬁcation of recombinant proteins. The recombinant bacu-
loviruses expressing the VACV IFNα/βBP (B18) have been previously
described16,21. The EVN194 coding sequence lacking its predicted signal peptide
was PCR-ampliﬁed from the ECTV genome and cloned into pAL7, a modiﬁed
pFastBac vector bearing the honeybee mellitin signal peptide at the 5′ region and a
C-terminal V5-6xHis tag, to generate the plasmid pIM32. The plasmid pIM26
encoding E194GAGmut was engineered using pIM32 as template and introducing
mutations in the E194 gene with the QuickChange II site-directed mutagenesis kit
(Stratagene) and oligonucleotides 5′-GGTTAACTGGGAGGCGATAGGAGCG
ACTGCGGCCCCTCTTAATGCAGCTGTTGCAAACGGTGACTTATGG -3′ and
5′-CCATAAGTCACCGTTTGCAACAGCTGCATTAAGAGGGGCCGCAG
TCGCTCCTATCGCCTCCCAGTTAACC -3′. Plasmids pIM32 and pIM26 were
sequenced to conﬁrm the presence of the desired mutations and the absence of
inadvertent mutations and then used to obtain the recombinant baculoviruses by
the Bac-to-Bac system (Invitrogen). As control, a recombinant baculovirus
expressing the ECTV SEMA protein C-terminally tagged to V5-6xHis was used.
Supernatants from Hi5 cells infected with the recombinant baculoviruses were ﬁrst
concentrated by ultraﬁltration and then buffer exchanged against 50 mM phos-
phate, 300 mM NaCl and 10 mM imidazole, pH 7.4, as described21, prior to
afﬁnity-puriﬁcation of recombinant proteins with Ni-NTA agarose (Qiagen).
Protein purity and quantity were analysed on Coomassie blue-stained SDS-PAGE
and quantiﬁed by gel densitometry.
Protein binding to cell surface by immunoﬂuorescence. HeLa or CHO-K1 cells
seeded onto glass coverslips in 24-well plates were incubated with 250 nM of
puriﬁed recombinant viral proteins for 30 min at 4 °C. Cells were then extensively
washed with ice-cold PBS and ﬁxed with 4% paraformaldehyde in PBS for 12 min
at room temperature. The membrane permeabilization step was omitted, thus after
aldehyde quenching with 50 mM NH4Cl for 5 min, cells were incubated with a
monoclonal anti-V5 antibody diluted 1:500 (Invitrogen) followed by anti-mouse
IgG-A488 (Molecular Probes) diluted 1:1000. Cell nuclei were stained with DAPI
(Calbiochem). Images were acquired in a Leica DMI6000B automated inverted
microscope equipped with a Hamamatsu Orca R2 digital camera.
Protein binding to cell surface by ﬂow cytometry. CHO-K1 cells were detached
with 4 mM EDTA at 37 °C and harvested in PBS. Cells (3x105 per experimental
point) were incubated for 30 min on ice with 250 nM of the indicated viral
recombinant proteins. Cells were then extensively washed with FACS buffer (PBS,
0.01% sodium azide and 0.5% bovine serum albumin) and incubated for 30 min at
4 °C with monoclonal anti-V5 antibody (Invitrogen) diluted 1:500 followed by anti-
mouse IgG-A488 (Molecular Probes) diluted 1:500 in PBS. Finally, cells were
resuspended in 0.5 ml FACS buffer and analysed in a FACSCalibur ﬂow cytometer
(BD Sciences).
SPR analyses. To determine the afﬁnity constants, recombinant proteins
(E194 and E194GAGmut) were immobilized on CM4 chips (GE Healthcare) by
amine coupling, as previously described62, in order to get 350–800 response units.
SPR experiments were performed using a Biacore X biosensor (GE Healthcare).
Different concentrations (in the range 0.5–40 nM) of mouse IFNα subtype A
(PBL Assay Science) were injected at 30 μl/min in HBS-EP and the collected
sensorgrams were aligned and ﬁtted to a 1:1 Langmuir model using the
BIAevaluation 3.2 software.
Neutralisation of type I IFN antiviral activity assay. The two types of assay used
in this work to measure IFN antiviral activity have been previously described18,21.
In the preincubation assay, 50 units of recombinant murine IFN-α subtype A
(PBL Assay Science) were incubated with supernatants from infected cells con-
taining viral proteins, puriﬁed viral recombinant protein or diluted plasmas from
infected mice for 30 min at 37 °C and then added to L929 cells seeded in 96-well
plates the day before (2500 cells/well). In the washing assay, culture supernatants or
recombinant proteins were added to cells, incubated for 30 min at 37 °C, and then
extensively washed prior to the addition of murine IFN-α. In both cases, 16 h after
IFN addition, cells were washed and infected with VSV (m.o.i. 50 pfu/cell) and cell
viability was determined at 72 hpi using the Cell Titer 96 Aqueous One Solution
cell proliferation assay (Promega) following manufacturer indications.
Supernatants from infected cells were collected at 72 dpi when cytopathic effect
was complete. Supernatants were centrifuged at low speed to remove detached cells
and cell debris and then inactivated by incubation with 2 μg/ml psoralen (4–9-
aminomethyl-Trioxsalen; Sigma) for 10 min and then UV-irradiated for 10 min
with 2.25 J/cm2 in a Stratalinker 1800. Complete inactivation (>108 fold reduction
in pfu) was conﬁrmed by plaque assay on BSC-1 cells. Virus inactivated
supernatants were concentrated 20–30 fold using Amicon ultra/ﬁltration devices
(Millipore) with a 10 kDa cut-off.
Transcription analysis (RNA-seq). Samples of the indicated tissues from two
groups of ﬁve Balb/c mice per condition were aseptically removed at 5 dpi and
conserved at 4 °C in RNAlater stabilisation solution (Qiagen). Total RNA extrac-
tion was performed with Reliaprep RNA tissue miniprep system (Promega) fol-
lowing manufacturer indications, and both quality and integrity of the RNA
samples were assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies).
Duplicated cDNA libraries per condition (one per animal group) were constructed
with TruSeq RNA Sample Prep Kit v2 Set A (Illumina) using equal amounts of
total RNA from ﬁve animals per library, strictly following the manufacturer’s
instructions. In the case of the lymph nodes, tissues were pooled prior to RNA
extraction and two cDNA libraries were also generated per condition. Libraries
were sequenced using TruSeq SBS Kit v3—HS (Illumina) on an Illumina Hiseq
2000 at the Max-Planck-Institute for Molecular Genetics, Berlin. The fastq ﬁles
containing the reads, after quality assessment with package FastQC, were mapped
to the mouse genome (build GRCm38 from Mus musculus C57BL/6 J strain) using
Tophat v2.0.4 with default parameters63. Only those reads matching the mouse
genome were considered in the differential gene expression analysis carried out
with Cuffdiff (Cufﬂinks v2.1.0 software63). Differentially expressed genes display-
ing statistically signiﬁcant alterations (p-value < 0.05 and fold change >2, using two
replicates for condition) were used to determine those pathways that were affected
by the viral infection. Pathway gene enrichment and upstream regulators analyses
were performed with the Ingenuity Pathway Analysis (IPA) software (Qiagen).
Gene expression heatmaps were generated with the R package Gplots.
Statistical analysis. Data were analysed using GraphPathD Prism software.
Footpad swelling and % initial weight data were analysed using multiple t tests with
false discovery rate (FDR) Q= 1% and Mann–Whitney U-test was used with data
related to virus titres in organs. Analyses were performed up to times post-infection
at which survival rates in the corresponding groups were above 50%.
Data availability
The data that support the ﬁndings of this study are available from the corre-
sponding author upon reasonable request. The viral genomic sequences reported,
together with the fastq ﬁles containing the reads from the RNA-seq experiments
have been submited to the European Nucleotide Archive under reference number
PRJEB26437. A Reporting Summary for this Article is available as a Supplementary
Information ﬁle.
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